Nurosene Partners With Brain Computer Interface Technology Ni2o To Pioneer Research For Alzheimer’s And Als

Ni2o will use Nurosene’s NetraAI technology to accelerate their research into neurodegenerative disease treatments. 

Nurosene Health Inc., a healthtech company focused on building a generation of healthier brains, announced that it has entered into a partnership with Ni2o, an Oxford University company, for the utilization of Nurosene’s NetraAI to support and accelerate research into neurodegenerative disease treatments.

Recommended AI News: Top 5 NFT Collectibles Worth $10.2 Billion in November

Ni2o’s wireless Kiwi brain implant will leverage NetraAI’s patient maps and computational power to provide more precise treatment protocols for neurodegenerative diseases. Kiwi is capable of intervening with damaged brain tissue by using light and electrical impulses, and has already shown amazing potential to develop into a genuine therapeutic protocol.

Ni2o was founded by Dr Newton Howard, one of the world’s leading figures in neuroscience, who developed a revolutionary brain-computer interface (BCI) to treat a wide range of neurodegenerative brain disorders and to improve cognitive performance. The renowned brain and cognitive scientist started this work at Oxford in his capacity as Professor of Computational Neuroscience and Neurosurgery, and then continued at MIT where he was Director of the Synthetic Intelligence Lab in addition to founding the Mind Machine Project.

“Dr. Howard’s work in the area of Deep Brain Stimulation (DBS) is exciting, and he clearly understands that the heterogeneity of debilitating brain diseases requires two things: a tool that can adjust for each person and a map that allows the tool to treat people with precision. Think of NetraAI as a navigational guidance system for this amazing technology. We already have maps for Alzheimer’s and ALS patients as part of our IP portfolio, and through this collaboration will make our systems even smarter,” said Dr. Joseph Geraci, Chief Scientific Officer at Nurosene.

Recommended AI News: Confluence Announces Partnership With Fund Service Provider, FundHero

Dr. Howard, Chief Executive Officer of Ni2o, has been working on a novel paradigm for the brain involving an integration of electrical, optical, and chemical properties. His leadership in this area has resulted in a way forward to potentially treat Alzheimer’s, Parkinson’s, and ALS patients through a minimally invasive procedure. Dr. Howard has spent 30+ years developing advanced technology for companies such as Boeing, Intel, Google, and Microsoft.

“Nurosene’s focus on brain health aligns entirely with the vision of Ni2o. Dr. Geraci and I have both been working in the neurodegenerative research space for some time, having work supported by government organizations, including IARPA. It’s exciting to be partnering to access their NetraAI machine learning platform to augment our ability to adapt our own tools for these complex diseases. Kiwi is at the cutting edge of technology and we are extremely motivated to make an impact on human health,” said Dr. Howard.

Nurosene’s NetraAI technology is a self-generating AI that has uncovered precise insights about diseases like Alzheimer’s, Parkinson’s, and ALS. NetraAI was recently awarded for its work in ALS in a global challenge involving a powerful genetic data set. These resulting maps are necessary in order to advance treatments for these diseases as patients can be quite different, despite having the same label.

Recommended AI News: Instamojo Brings Seamless Logistics For Small Businesses With Five Key Partnerships For Delivery